A study published in Cell Metabolism looks at time-restricted feeding and memory in mouse models of Alzheimer’s disease. Dr … read more
Results from Eli Lilly’s TRAILBLAZER-ALZ 2 Randomized Clinical Trial looking at the use of donanemab in early symptomatic Alzheimer’s disease … read more
The U.S. Food and Drug Administration (FDA) has converted lecanemab from an accelerated approval to a traditional approval for the … read more
A press release from Eli Lilly states that their antibody treatment, donanemab, significantly slowed cognitive and functional decline in phase … read more
Results of a phase 1b trial, looking at Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease, has been published in … read more
An observational study published in The Lancet Public Health looks at hearing aid use and all-cause and cause-specific dementia. … read more
A study published in Cell Stem Cell looks at the use of deep brain stimulation in a mouse model of … read more
A study published in JAMA Neurology looks at age at menopause and hormone therapy use, and tau and β-Amyloid in … read more
A study published in The Lancet Public Health looks at neurodegenerative disease among male elite football players in Sweden. … read more
An observational study published in BMC Medicine looks at adherence to a Mediterranean diet and risk of dementia. Dr … read more
A study published in The Journal of Physiology looks at the effect of fasting on exercise-induced increases in circulating BDNF … read more
The U.S. Food and Drug Administration (FDA) have approved lecanemab via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. … read more
A correspondence paper, published in the New England Journal of Medicine (NEJM), looks at the case of a patient receiving lecanemab … read more
A conference abstract (not a published paper) presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2022 compares the … read more
Results of the phase 3 trial of lecanemab for early Alzheimer’s disease has been published in New England Journal of … read more
Dementia research is at a tipping point. Earlier this year, an Alzheimer’s drug, Eisai’s lecanemab, demonstrated a small but clear … read more
A study published in JAMA Network Open looks at the development of a clinical risk score prediction tool for dementia. … read more
Roche have announced that the results of their phase 3 trial evaluating gantenerumab in people with early Alzheimer’s disease did … read more
A study published in the Journal of Alzheimer’s Disease looks at soluble amyloid-beta, amyloid plaques, and cognition in people with … read more
A press release from Eisai and Biogen has announced positive topline results from their Phase 3 clinical trial of lecanemab … read more
